直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
    • AI + Finnegan
    • Appeals, Issues, and Legal Strategy
    • Diligence, Licensing, and Opinions
    • Global IP Enforcement, Litigation, and Trials
    • Patent Office Invalidation Proceedings
    • Prosecution and Portfolio Management
    • Trademark and Brand Management
    • AI, Electronics, and Information Technology
    • Chemicals, Industrials, and Materials
    • Communications
    • Consumer Goods and Services
    • Energy
    • Hospitality, Gaming, and Leisure
    • Life Sciences
    • Transportation and Logistics
  • Experience

Experience

Securing $240 million and a jury verdict of willful infringement for Promptu in patent case against Comcast

Promptu Systems Corporation

US Synthetic secures ITC exclusion order barring polycrystalline diamond compacts (PDCs)

US Synthetic Corporation

Achieving precedent in preserving valuable patents for Lumify®

Eye Therapies, LLC

Finnegan client Maglula delivers crushing blow to Amazon’s arbitration practices over counterfeit products

Maglula, Ltd.

Finnegan secures $180M for CSRC in complex arbitrations

CSRC et al.

Protecting a blockbuster diabetes treatment for AstraZeneca

AstraZeneca AB

Major victories across IP venues for Volkswagen, Audi, Bentley, and Lamborghini

Audi AG; Audi of America, LLC; Automobili Lamborghini America, LLC; Automobili Lamborghini S.p.A.; Bentley Motors Limited; Bentley Motors, Inc; Volkswagen AG; Volkswagen Group of America, Inc.

Finnegan tees up valuable patents for Eisai, leading to major strategic collaboration agreement

Eisai Co., Ltd.

Finnegan helps Intellia Therapeutics acquire Rewrite Therapeutics, Inc. for $45 million

Intellia Therapeutics, Inc.

Recent Experience

Experience

Certain Plant-Derived Recombinant Human Serum Albumins ("rHSA") and Products Containing Same Certain Plant-Derived Recombinant Human Serum Albumins ("rHSA") and Products Containing Same

337-TA-1238, ITC, Judge McNamara

Experience

Prosecuting patents for startup Hutchison Medipharma

Prosecuting patents for startup Hutchison Medipharma

Hutchison Medipharma

Experience

Two-Way Radio Equipment and Systems, Related Software, and Components Thereof Two-Way Radio Equipment and Systems, Related Software, and Components Thereof

337-TA-1053, ITC, Judge McNamara

Experience

Complete victory for Finnegan clients Nutrichem and Heyi at the ITC Complete victory for Finnegan clients Nutrichem and Heyi at the ITC

337-TA-914, ITC, Judge Lord

Experience

Certain Light Emitting Diode Chips, Laser Diode Chips and Products Containing Same Certain Light Emitting Diode Chips, Laser Diode Chips and Products Containing Same

337-TA-674, ITC, Judge Luckern

Experience

Certain Short-Wavelength Light Emitting Diodes, Laser Diodes and Products Containing Same Certain Short-Wavelength Light Emitting Diodes, Laser Diodes and Products Containing Same

337-TA-640, ITC, Judge Luckern

Experience

When the patent for Zyprexa® and $2 billion in annual revenue were on the line, Eli Lilly turned to Finnegan When the patent for Zyprexa® and $2 billion in annual revenue were on the line, Eli Lilly turned to Finnegan

1:01-cv-00443, S.D. Ind., Judges LaRue, Lynch, Shields, Young
05-1429, -1430, Fed. Cir., Judges Rader, Schall, Gajarsa

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP